Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Inosine Pranobex→

Inosine Pranobex Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
36703-88-5
Molecular formula
C52H78N10O17
Molecular weight
1115.2 g/mol
Drug class
Immunomodulatory antiviral agentinosine pranobex complex
Mechanism of action
The exact mechanism is not fully established. It appears to modulate cell-mediated immune responses, including T-cell differentiation and lymphoproliferative responses, rather than acting directly on viral enzymes.
Indications / reported uses
  • Adjunctive treatment of selected viral infections in countries where inosine pranobex is authorised; exact indications vary by product and jurisdiction.

Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/inosine-pranobex · https://meshb.nlm.nih.gov/record/ui?ui=D007542 · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Inosine Pranobex Environmental Risk Assessment (ERA) (the Inosine Pranobex ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.